Nordea Investment Management AB Acquires 232,690 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Nordea Investment Management AB boosted its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 42.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 777,816 shares of the biopharmaceutical company’s stock after purchasing an additional 232,690 shares during the period. Nordea Investment Management AB owned about 0.59% of Dynavax Technologies worth $10,034,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of DVAX. GAMMA Investing LLC lifted its stake in shares of Dynavax Technologies by 175.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 1,685 shares during the period. US Bancorp DE grew its position in shares of Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,034 shares during the period. Capital Performance Advisors LLP acquired a new position in shares of Dynavax Technologies during the 3rd quarter valued at $45,000. Nisa Investment Advisors LLC boosted its stake in Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,679 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Dynavax Technologies in the third quarter worth $89,000. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Stock Down 1.6 %

DVAX stock opened at $12.62 on Friday. The firm has a market capitalization of $1.66 billion, a PE ratio of 97.08 and a beta of 1.34. The stock’s 50 day moving average is $12.72 and its 200-day moving average is $11.62. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $14.41. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a research note on Friday, November 8th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.